Basic Information
| LncRNA/CircRNA Name | DARS-AS1 |
| Synonyms | NA |
| Region | GRCh38_2:135985176-136022593 |
| Ensemble | ENSG00000231890 |
| Refseq | NR_110199 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qPCR |
| Sample | thyroid tissues,PTC cell lines (BHP5-16, TPC, K1, and BHP2-7) and one normal human thyroid epithelial cell line (Nthy-ori 3-1) |
| Expression Pattern | up-regulated |
| Function Description | the level of DARS-AS1 in tumor tissues of thyroid cancer patients was remarkably higher than that in adjacent tissues, and the difference was statistically significant. Compared with patients with low expression of DARS-AS1, patients with high DARS-AS1 expression had a higher incidence of high tumor stage, distant metastasis, and a lower overall survival rate. Besides, compared with NC group, the proliferation and migration ability of shRNA-AS1 expression knockdown group sh-DARS-AS1 was remarkably decreased. |
| Pubmed ID | 31841198 |
| Year | 2019 |
| Title | LncRNA DARS-AS1 Regulates microRNA-129 to Promote Malignant Progression of Thyroid Cancer |
External Links
| Links for DARS-AS1 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |